Critical care management of patients with hemophagocytic lymphohistiocytosis.
OBJECTIVE
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition associated with multiple organ dysfunction. We sought to describe ICU management and outcomes in HLH patients meeting HLH-2004 criteria and to identify determinants of mortality.


METHODS
Retrospective study between January 1998 and January 2009.


METHODS
Medical ICU of a teaching hospital.


METHODS
Among the 72 patients fulfilling the HLH-2004 criteria, we report the 56 patients with complete follow-up and no missing data.


METHODS
None.


RESULTS
Clinical and laboratory data were abstracted from the medical records. Median SOFA score at admission was 6.5 (IQR, 4-8). At ICU admission, the number of HLH-2004 criteria was 6 (5-7). Sixty-six precipitating factors were found in 52 patients and consisted of 43 tumoral causes (8 Castleman's diseases, 18 B cell lymphoma and 17 various malignancies), 13 non-viral infections and 10 viral infections. Underlying immune deficiency was present in 38 (67.8%) patients. Etoposide was used in 45 patients, corticosteroids in 31 and intravenous immunoglobulins in 3. Mechanical ventilation was required in 32 patients, vasoactive agents in 30 and renal replacement therapy in 19. Hospital mortality was 29/56 patients. By multivariate analysis, factors associated with increased hospital death were shock at ICU admission [OR, 4.33; 95% confidence interval (95% CI), 1.11-16.90; P = 0.03] and platelet count <30 g/l (OR, 4.75; 95% CI, 1.20-18.81; P = 0.02). B cell lymphoma [odds ratio (OR), 0.17; 95% CI, 0.04-0.80; P = 0.02] and Castleman's disease (OR, 0.11; 95% CI, 0.02-0.90; P = 0.04) were associated with increased hospital survival.


CONCLUSIONS
Aggressive supportive care combined with specific treatment of the precipitating factor can produce meaningful survival in patients with HLH responsible for multiple organ failures. Survival is highest in patients with HLH related to Castleman's disease or B cell lymphoma.
Buyse
Sophie
S
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Teixeira
Luis
L
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Galicier
Lionel
L
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Mariotte
Eric
E
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Lemiale
Virginie
V
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Seguin
Amélie
A
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Bertheau
Philippe
P
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Canet
Emmanuel
E
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
de Labarthe
Adrienne
A
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Darmon
Michaël
M
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Rybojad
Michel
M
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Schlemmer
Benoit
B
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.
Azoulay
Elie
E
Medical Intensive Care Unit, Clinical Immunology, Pathology and Dermatalogy departments, Saint-Louis Teaching Hospital, University Paris-7 Paris-Diderot, UFR de Médecine, AP-HP, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010, Paris, France. elie.azoulay@sls.aphp.fr.
D000328:Adult; D000368:Aged; D003422:Critical Care; D005260:Female; D006801:Humans; D051359:Lymphohistiocytosis, Hemophagocytic / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome